All stories

1 outlets · filed 29 October 2026

We're raising our price target on Eli Lilly as the obesity-drug boom rolls on

This story is from the archive. It was covered between 29 October 2026 and 29 October 2026, and nothing below has been updated since. See what is happening now.

The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

How it broke

CNBC

In this story

1outlets
0videos
1articles

More on Health

Every Health story, across every outlet